Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m
Change To Partnership Comes After First Positive Pivotal Data For Blood Disorders
Vertex thinks CTX001 may offer a cure for sickle cell disease, beta thalassemia 
